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Abstract
Background:  Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone
formation in vitro and in rodents. Results of epidemiologic analyses evaluating the association
between use of these cholesterol-lowering drugs, bone mineral density and fracture have been
mixed.
Methods: Women (n = 24) with osteopenia, assessed by broad band ultrasound attenuation, were
randomized to simvastatin 20 mg, 40 mg or identical-appearing placebo for 12 weeks. Fasting lipid
profiles and biochemical markers of bone formation (bone-specific alkaline phosphatase) and
resorption (N-telopeptides and C-terminal propeptide of type 1 collagen) were measured at
baseline, 6 and 12 weeks.
Results: Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs
baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20
mg and 40 mg, respectively. At baseline, bone marker concentrations were similar in the three
treatment groups. At 6 and 12 weeks, bone marker concentrations were not different from
baseline, and no significant differences in bone marker concentrations were observed between
treatment groups at either 6 or 12 weeks.
Conclusion: Among osteopenic women, treatment with simvastatin for 12 weeks did not affect
markers of bone formation or resorption.
Background
Hydroxymethylglutaryl coenzyme A (HMG coA) reduct-
ase inhibitors increase new bone formation in vitro and
enhance trabecular bone formation in rodents [1]. These
effects have been attributed to blockade of the mevalonate
pathway upstream from the site of bisphosphonate ac-
tion, which is thought to be mediated by inhibition of far-
nesyl pyrophosphate and geranylgeranyl pyrophosphate
synthesis [2,3]. Currently available treatments for bone
loss do not induce new bone formation; consequently,
Mundy's observations excited considerable interest in the
potential utility of a class of drugs with proven long term
safety for a new purpose, treatment of osteopenia or oste-
oporosis.
The initial analysis in humans of the relationship between
HMG coA reductase inhibitors and fractures was carried
out on the Study of Osteoporotic Fractures and the Frac-
ture Intervention Trial cohorts. In that report Bauer et al.
described a nonsignificant reduction in hip (RR 0.30, 95%
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CI 0.08,1.18) and non-spine fracture (RR 0.83, 95% CI
0.61, 1.15) associated with current HMG coA reductase
inhibitor use [4]. A trio of analyses of health-maintenance
organization members, New Jersey Medicaid/Pharmacy
Assistance/Medicare recipients, and the United Kingdom
General Practice Research Database, identified a signifi-
cantly lower risk of fracture among HMG coA reductase
inhibitor users, with odds ratios ranging from 0.48 to 0.55
[5–7]. However, subsequent analyses of the UK General
Practice Research Database and Women's Health Initia-
tive Observational Study, found no significant reduction
in fracture [8,9] or bone demineralization [10] associated
with HMG coA reductase inhibitor use.
A retrospective study of changes in bone mineral density
in Korean men and women with type 2 diabetes mellitus
revealed higher bone density in HMG coA reductase in-
hibitor-users compared with non-users after 14 months of
follow up [11].
Post-hoc analyses from randomized cholesterol-lowering
trials have evaluated effects of HMG coA reductase inhib-
itors on bone markers and fractures. A 12-week rand-
omized trial in non-osteoporotic individuals found no
effect of simvastatin or atorvastatin on C-teleopeptide.
Bone-specific alkaline phosphatase was reduced 6% (p <
0.001) among patients assigned to simvastatin, but not
atorvastatin [12]. A large randomized trial of pravastatin
in non-osteoporotic subjects (n = 9014, median age 62
years), identified no reduction in fracture risk [13]. How-
ever, pravastatin, in contrast to other HMG coA reductase
inhibitors, did not induce bone morphogenetic protein-2
formation in vitro[14], and consequently might not be ex-
pected to affect fracture risk.
This report describes results of a double-blind, placebo-
controlled, randomized trial of simvastatin's effects on
bone markers in women at high risk for osteoporosis.
Materials and Methods
Participants
Eligible women were identified as high risk for osteoporo-
sis by virtue of a T score of -1 to -2.5 measured by broad
band ultrasound attenuation (Hologic Sahara). Women
could not be taking estrogen, synthetic estrogen receptor
modulators, calcitonin, bisphosphonates or HMG coA re-
ductase inhibitors. A negative pregnancy test was required
for women of child-bearing potential, and normal serum
asparate aminotransferase was required for all subjects. A
stable dose of calcium and vitamin D supplementation
was permitted. This was a single site trial, conducted at the
George Washington University Lipid Research Clinic. Par-
ticipants provided informed consent in a form approved
by the George Washington University Committee on Hu-
man Research.
Interventions
Eligible women were randomly assigned (permuted
block) to placebo, simvastatin 20 mg or simvastatin 40
mg taken orally each evening. Fasting plasma samples
were collected for lipid profiles at baseline and after 12
weeks on treatment. Two serum samples were collected
for bone markers, 1 week apart, prior to initiation of ther-
apy; baseline levels were the average of these two values.
On-treatment samples were collected at 6 and 12 weeks.
All serum samples were collected at the same time of day
to minimize diurnal variation, and stored at -70°C until
assayed.
Simvastatin 20 mg, simvastatin 40 mg and identical-ap-
pearing placebo tablets were provided by Merck (West
Point, PA). Bone-specific alkaline phosphatase (bone
ALP) (Alkphase-B, Metra Biosystems, Mountain View,
CA), cross-linked N-telopeptides (NTx-I)(Osteomark NTx
Serum, Ostex International, Seattle, WA) and C-terminal
propeptide (CTx-I)(Metra Biosystems, Mountain View,
CA) of type I collagen were measured by monoclonal im-
munoassay. Plasma lipids were measured as previously
described [15].
The study objective was to compare the effects of simvas-
tatin and placebo on bone markers. The hypothesis was
that simvastatin would reduce bone resorption and in-
duce new bone formation in this study population. Differ-
ence in plasma bone marker concentration between
treatment groups was the primary outcome.
Randomization
Allocation sequence was generated by a statistician in the
Medical Center Biostatistics Unit; serial envelopes identi-
fying double-blind treatment assignment to drug A, B or
C were prepared by a staff member who did not work on
Table 1: Characteristics of the Study Population
Mean ± SD
Age, y 56.1 ± 9.7
T score -1.7+0.1
Blood pressure, mm Hg
systolic 109 ± 6
diastolic 68 ± 3
Body mass index, kg/m2 25.6 ± 1.1
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this trial. This individual also prepared labeled containers
of study pills. The study coordinator, who randomized
subjects by opening sequential envelopes, remained
blinded to treatment assignment until after laboratory as-
says were completed, as did the physician investigator. No
subjects were unblinded during the trial.
Statistical methods
The sample size of 8 subjects per treatment group was cho-
sen to be adequate to detect with 95% confidence a 29%
reduction in NTx-I, allowing for a dropout rate of 10% in
the design. A 40% reduction in NTx-I was considered to be
clinically relevant. Changes within treatment groups were
assessed by paired t test; differences between treatment
groups were assessed by unpaired t test. StatView software
(SAS Institute) was used for analyses.
Results
Characteristics of the study population are summarized in
Table 1. Twenty-four women, ranging in age from 46 to 76
years, were recruited between February and May, 2001.
Age, blood pressure, heart rate, body mass index, creati-
nine and T score were similar in the three treatment
groups. Two women in the simvastatin 20 mg group did
not complete the study: one developed intolerable drug
side effects and one unexpectedly moved abroad. No on-
treatment blood samples were available for either of these
women. The remaining 22 women are included in analy-
ses of plasma lipids and bone markers. Among these 22
women, adherence to study medication, assessed by pill
count, was 94%.
Plasma lipids at baseline and on treatment are summa-
rized in Table 2. After 12 weeks, total cholesterol fell 2%,
25% (p < 0.01 vs. baseline) and 26% (p < 0.01 vs base-
line) on placebo, simvastatin 20 mg and 40 mg, respec-
tively. Low density lipoprotein (LDL)-cholesterol was
reduced by 7%, 39% (p < 0.01 vs. baseline) and 47% (p <
0.01 vs baseline), respectively. No significant changes
from baseline to 12 weeks were observed for triglycerides
or high density lipoprotein-cholesterol within treatment
groups. When treatment groups were compared, total and
LDL-cholesterol were significantly lower at 12 weeks in
women randomized to simvastatin 40 mg compared with
those assigned to placebo (p < 0.01 for both). LDL-choles-
terol was also lower among women in the simvastatin 40
mg group compared with the simvastatin 20 mg group (p
< 0.05). All subjects' serum asparate aminotransferase lev-
els remained normal at 12 weeks.
Bone marker concentrations are shown in Table 3. At
baseline, levels of bone ALP, NTX-I and CTX-I were similar
in the 3 treatment groups. At 6 and 12 weeks, bone marker
levels remained similar in the 3 treatment groups. Plasma
Table 2: Plasma lipids
Placebo Simvastatin 20 mg Simvastatin 40 mg
Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Total cholesterol, mmol/L 5.69 ± 0.49 5.53 ± 0.49 6.08 ± 0.52 4.55 ± 0.26 5.28 ± 0.36 3.88 ± 0.21a
Triglycerides, mmol/L 1.13 ± 0.17 1.21 ± 0.15 0.88 ± 0.06 0.96 ± 0.10 0.90 ± 0.15 0.84 ± 0.16
HDL-cholesterol, mmol/L 1.60 ± 0.08 1.78 ± 0.08 1.60 ± 0.16 1.63 ± 0.18 1.76 ± 0.13 1.84 ± 0.13
LDL-cholesterol, mmol/L 3.54 ± 0.47 3.28 ± 0.39 4.09 ± 0.57 2.48 ± 0.36 3.10 ± 0.34 1.63 ± 0.13a,b
Mean ± SE ap < 0.01 vs placebo b p < 0.05 vs simvastatin 20 mg
Table 3: Bone markers
Placebo Simvastatin 20 Simvastatin 40
Baseline 6 weeks 12 weeks Baseline 6 weeks 12 weeks Baseline 6 weeks 12 weeks
NTX-I, nM BCE 15.5 ± 1.8 15.7 ± 2.0 15.9 ± 1.4 16.5 ± 1.7 15.9 ± 1.2 19.6 ± 1.8 19.3 ± 2.4 17.6 ± 2.1 18.1 ± 2.0
CTX-I, ng/ml 95.4 ± 5.9 86.4 ± 7.9 86.9 ± 
11.5








Bone ALP, U/L 14.3 ± 2.4 14.0 ± 2.5 14.4 ± 2.9 19.0 ± 3.0 17.4 ± 2.8 17.2 ± 2.8 14.3 ± 2.2 13.4 ± 2.2 14.0 ± 2.2
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concentrations of the three bone markers at baseline, 6
and 12 weeks are shown (Fig. 1) for the 8 women assigned
to simvastatin 40 mg/day. Neither upward or downward
trend is apparent for any of the three bone markers.
Discussion
This randomized, double-blind, placebo-controlled,
dose-ranging trial identified no effect of simvastatin on
markers of bone formation or resorption at doses which
significantly inhibited HMG coA reductase activity. These
results confirm and extend those of Chan et al. who found
no effect of simvastatin 20 mg on bone ALP or urine NTX-
I [16] in hypercholesterolemic Chinese subjects. Strengths
of the current study include the osteopenic cohort, greater
ethnic diversity, placebo-controlled design and inclusion
of a higher dose of simvastatin as well as the 20 mg dose.
In addition to the possibility that statins actually have nei-
ther favorable nor unfavorable impact on bone metabo-
lism in humans, there are several potential alternative
explanations for these observations. First, simvastatin
may not be the optimal choice of HMG coA reductase in-
hibitor. Simvastatin was effective both for stimulating
bone morphogenetic protein-2 formation in vitro, and in-
ducing bone formation in rodents [1], rendering this pos-
sibility less likely. However, the elimination half-life of
simvastatin is relatively short [17], and allows for the pos-
sibility that agents with longer half-lives, such as atorvas-
tatin [18], might demonstrate efficacy. Second, the dose of
simvastatin used may have been inadequate. At the time
this trial was designed, simvastatin 40 mg was the highest
dose marketed. Subsequently, the 80 mg dose has become
available with similar safety profile to the 40 mg dose; the
possibility that a higher dose might affect bone turnover
cannot be excluded.
Third, the sample size may have been too small to detect
changes in plasma concentrations of bone markers. For
example, in a 12 week randomized comparison of 2 doses
of simvastatin and 2 doses of atorvastatin, with about 200
subjects in each study arm, simvastatin reduced bone ALP
by 4.1% and 6.3% from baseline levels at the 40 mg and
80 mg doses, respectively [12]. That trial was designed to
evaluate lipid effects, not bone markers, so included men
and women with unknown bone density status. In inter-
preting these results, the observed reduction in bone ALP
may indicate inhibition of bone resorption, but this was
not reflected by a parallel reduction in CTX-I. Further, if
new bone was being created, as was observed in the rat
model, one might expect bone ALP to rise, as in Paget's
disease [19], rather than the observed fall. The change in
concentration of a bone marker which reflects a clinically
meaningful change, is also an issue. With alendronate, for
example, 80% reductions in markers of bone resorption
were observed within 6 weeks [20]. Thus, a change of a
Figure 1
Bone markers in women randomized to simvastatin
40 mg daily. Plasma concentrations of bone ALP, CTX-I
and NTX-I at baseline, and after 6 and 12 weeks of simvasta-
tin 40 mg qhs are shown for each woman assigned to that
treatment group.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/7
Page 5 of 5
(page number not for citation purposes)
few percentage points may not be clinically important. A
comparable reduction in NTX-I to that observed with al-
endronate would have been readily detected with the
sample size studied.
Fourth, the ultrasound entry screen for low bone mineral
density may have yielded false-positive results, leading to
inclusion of some women with normal bone density.
Manufacturer specifications suggest that in 90% of wom-
en with Sahara T-score less than -1, osteoporosis will be
confirmed by dual x-ray absorptiometry [21]. Finally, the
duration of treatment may have been insufficient. Alendr-
onate significantly reduces bone marker concentrations
within a few weeks [20], but effects of HMG coA reductase
inhibitors may not be apparent so quickly.
Conclusions
Our study revealed neither deleterious nor favorable effect
of simvastatin on bone turnover during 12 weeks of ther-
apy, and does not support a role for simvastatin as a clin-
ically useful modulator of bone remodeling. Further study
is needed to determine whether other agents or regimens
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